Johnny Högberg new CEO of Flemingsberg Science

On 1st November, Johnny Högberg will take over as Chief Executive Officer of the Flemingsberg Science Foundation.

The Foundation’s task is to develop southern Stockholm where clinical care and research are already strongly established with world-leading Karolinska University Hospital, the Karolinska Institute, the Royal Institute of Technology (KTH), Södertörn University and several other academies. Flemingsberg Science will contribute to making the Stockholm region one of the five leading Life Science regions in the world.

Johnny Högberg comes from Skellefteå Science City, where he was CEO, and replaces Björn Varnestig, who is giving up his post as CEO in connection with his 65th birthday.

“I am really looking forward to taking on the role of CEO of Flemingsberg Science. The Stockholm region is a strong area of growth in Europe with high ambitions for Life Science in particular. The fact that the region has the stated goal of attracting the EU’s new Health Emergency Preparedness and Response Authority (HERA) is one of several examples of how these ambitions are expressed in practice,” says Johnny Högberg, incoming CEO of Flemingsberg Science.

The foundation’s Chair, Financial Region Councillor Irene Svenonius (M), is pleased with the recruitment of the new CEO.

“We want to improve conditions for growth and development in Flemingsberg and the surrounding area. This will take place in a broad collaboration between the academies, municipalities and the regional authority, with both healthcare and expanded public transport. To achieve our high goals of attracting new companies, EU authorities, headquarters, investments and research, we need people with Johnny’s experience and knowledge,” says Irene Svenonius.

A Pitch Workshop for Entrepreneurs and Innovators in Flemingsberg

Earlier this spring, the Flemingsberg Science Foundation hosted a pitch workshop aimed at supporting entrepreneurs and innovators with promising ideas in Flemingsberg to elevate their concepts to the next level. This workshop coincided with our prestigious competition, Flemingsberg Science Award.

NextCell Pharma: A Decade at the Forefront of the Stem Cell Revolution

For the past ten years, NextCell Pharma has been developing cell therapies for autoimmune and inflammatory diseases, operating Sweden's largest stem cell biobank through its subsidiary, Cellaviva, and conducting five clinical trials. They celebrate this milestone by launching their third subsidiary, QVance.

In Flemingsberg, we cure diseases that were previously considered incurable

Earlier this year we hosted the most meaningful ATMP event of the spring, in collaboration with Miltenyi Biotec and the Karolinska ATMP Center, Karolinska University Hospital and Karolinska Institutet. We gathered over 120 participants, all sharing a vision of creating momentum to accelerate access to ATMPs in the Nordics.